What are the best‑practice pharmacologic approaches for acute exacerbations and chronic management of asthma?

Best Practice Pharmacological Approaches for Asthma Management

Chronic Asthma Management

Inhaled corticosteroids (ICS) are the most consistently effective long-term control medication for persistent asthma and should be the foundation of treatment for all patients with persistent disease. 1, 2

Stepwise Treatment Algorithm

Step 1 (Intermittent Asthma):

• Short-acting beta-agonist (SABA) as needed only 1, 3
• If SABA use exceeds 2 days per week (excluding exercise prophylaxis), escalate to Step 2 1, 2

Step 2 (Mild Persistent Asthma):

• Low-dose ICS as preferred controller therapy 2
• Leukotriene receptor antagonists are an alternative but not preferred option 1
• Continue as-needed SABA for symptom relief 1

Step 3 (Moderate Persistent Asthma):

• Low to medium-dose ICS plus long-acting beta-agonist (LABA) as preferred combination 2
• Critical warning: LABAs must never be used as monotherapy—they increase exacerbations and mortality risk when used alone 1, 2
• Alternative: Increase ICS dose to medium range (this option should be given equal weight to adding LABA) 1

Step 4-5 (Severe Persistent Asthma):

• High-dose ICS plus LABA 2
• Add oral systemic corticosteroids if needed for control 2
• Consider omalizumab for severe allergic asthma uncontrolled on high-dose ICS/LABA 1

Key Monitoring Parameters

Watch for inadequate control indicators that signal need to step up therapy: 1, 2

• SABA use more than 2 days per week for symptom relief
• SABA use more than 2 nights per month
• Nocturnal awakenings
• Activity limitations
• Peak expiratory flow (PEF) <80% predicted or personal best

Before stepping up therapy, always verify: 3

• Proper inhaler technique
• Medication adherence
• Environmental trigger exposure

Step down therapy only after 3 months of well-controlled asthma 3

---

Acute Exacerbation Management

Oral systemic corticosteroids are essential for moderate to severe asthma exacerbations and should be initiated early. 1, 2

Home Management Protocol

Patients should initiate treatment at home using a written asthma action plan when: 1, 3

• Symptoms and PEF worsen progressively day by day
• PEF falls below 60% of personal best
• Sleep is disturbed by asthma
• Morning symptoms persist until midday
• Diminished response to SABA (decreased duration of effect)

Immediate home treatment: 1, 2

• Increase SABA frequency (repetitive or continuous administration)
• Start oral corticosteroids immediately
• Doubling the ICS dose is NOT effective and should not be done 4

Corticosteroid Dosing for Acute Exacerbations

Adults: 2

• Prednisone 40-60 mg daily (or 30-60 mg prednisolone) 1, 2
• Continue until PEF reaches 70% of predicted or personal best
• Duration: 5-10 days typically, up to 21 days if needed 1, 2
• No need to taper if course is ≤2 weeks 1, 2

Children: 2

• 1-2 mg/kg/day (maximum 60 mg/day)
• Duration: 3-10 days
• No tapering needed for short courses 1, 2

Emergency Department/Urgent Care Management

Severity classification is critical—do not underestimate: 1

• Severe: Cannot complete sentences, respiratory rate >25/min (adults) or >50/min (children), heart rate >110/min (adults) or >140/min (children), PEF <50% predicted 1
• Objective lung function measures (spirometry or PEF) are more reliable than symptoms alone 1, 3

Treatment sequence: 1

1. Supplemental oxygen to correct hypoxemia
2. Repetitive or continuous SABA administration (salbutamol 5 mg or terbutaline 10 mg nebulized, repeated 4-6 hourly) 1
3. Oral systemic corticosteroids immediately 1
4. Add ipratropium bromide 500 μg to beta-agonist if inadequate response 1

Route of administration: 1

• Oral corticosteroids are equally effective as intravenous—use oral route
• Intravenous administration offers no advantages

---

Critical Pitfalls to Avoid

Common errors that worsen outcomes: 1, 4

• Overreliance on bronchodilators without adequate anti-inflammatory therapy
• Using LABAs as monotherapy (increases mortality)
• Doubling ICS dose during exacerbations (ineffective)
• Delaying oral corticosteroids in moderate-severe exacerbations
• Failing to provide written asthma action plans

High-risk patients requiring intensive monitoring: 1

• Previous severe exacerbation requiring intubation or ICU admission
• ≥2 hospitalizations or >3 ED visits in past year
• Using >2 canisters of SABA per month
• Difficulty perceiving airway obstruction severity

---

Alternative Therapies with Limited Evidence

High-dose ICS for exacerbations (2,400-4,000 μg beclomethasone equivalent for 1-2 weeks) may have benefit, but evidence is less robust than oral corticosteroids 4

Leukotriene receptor antagonists and anti-IgE reduce exacerbation risk, but magnitude of benefit compared to ICS/LABA combination is not yet established 5

Immunosuppressive drugs (cyclosporin, methotrexate) and complementary therapies (ionizers, acupuncture, homeopathy) have disappointing results in controlled trials and no clear role in routine treatment 1, 6